Crossmark

Exploration of efficacy of different therapy regimens for advanced NSCLC patients with KRAS mutation in the first-line treatment

Published Online: 2024-04-16

Authors

Wang, Ke

Xu, Manyi

Wang, Yanhua

Xu, Chunwei

Hao, Yue https://orcid.org/0000-0002-4725-6084
Song, Zhengbo https://orcid.org/0000-0002-2226-0570
Funding

Funding for this research was provided by:

the Medical Scientific Research Foundation of Zhejiang Province (No.2022KY653)
License Information

Text and Data Mining valid from 2024-04-16

Version of Record valid from 2024-04-16
More Information

Article History

Received: 9 February 2024

Accepted: 25 March 2024

First Online: 16 April 2024

Declarations

:

: All authors declare no conflict of interest.

: Approval of the study protocol was obtained from Zhejiang Cancer Hospital Institutional Review Board Committee (approval number: IRB-2022–33). Individual consent for this retrospective analysis was waived.

: Individual consent for analysis was waived.

: Not applicable.

Document is current